和誉-B：FGFR4抑制剂依帕戈替尼完成全球I期研究扩展阶段美国首例患者给药

Core Viewpoint - The company announced that its subsidiary, Shanghai Heyu Biopharmaceutical Technology Co., Ltd., has successfully completed the first patient dosing in a global multicenter Phase I clinical study of its self-developed FGFR4 inhibitor, Irpagratinib, targeting FGF19 overexpressing advanced hepatocellular carcinoma (HCC) [1] Group 1 - The Phase I clinical study is designated as ABSK-011-101 [1] - Irpagratinib has received Fast Track Designation from the FDA, which is expected to accelerate its global clinical development process [1]